Beclin-1在肾癌组织中的表达及其临床意义

Expression level and clinical significance of Beclin-1 in renal cell carcinoma

目的研究Beclin-1在肾癌中的表达及其临床意义。方法通过免疫组化检测肾癌中自噬相关基因Beclin-1的表达情况,初步探讨Beclin-1在肾癌组织中表达情况。并分析Beclin-1表达与肾癌复发及生存时间的相关性;多因素分析探讨其是否为肾癌预后的独立危险因素。结果对133例肾癌及12癌旁组织进行检测,肾癌组织中Beclin-1基因表达水平明显低于癌旁组织(P<0.05)。Beclin-1基因阴性肾癌患者的复发率明显高于Beclin-1基因阳性患者(P=0.041);Beclin-1阳性肾癌患者总体生存率明显高于Beclin-1阴性肾癌患者(P=0.008)。多因素分析显示,Beclin-1,肿瘤分级、分期及淋巴结转移与否是肾癌复发、死亡的独立预后因素。结论 Beclin-1低表达是肾癌预后不良的独立危险因素,它可能成为肾癌个体化治疗的潜在靶点。

Objective To investigate the clinical significance of Beclin-1 in renal cell carcinoma patients. Methods Immunohistochemical was employed to detect Beclin-1 expression level in renal cell carcinoma. To preliminarily assess the correlation between Beclin-1 and clinical pathological features in renal cell carcinoma. Furthermore, prognostic roles （recurrence, metastasis and survival） of Beclin-1 as a single agent index in renal cancer were analyzed using Kaplan-Meier survival curve. Finally, multi-variable analysis was conducted to explore whether Beclin-1 is independent prognostic risk factor for renal cancer. In 133 cases of renal cell carcinoma and 12 normal adjacent tissues, Beclin-1 gene expression levels and protein were significantly lower than the adjacent normal renal tissue （P〈0.05）. The recurrence rate of Beclin-1 positive renal cancer patients was significantly lower than those with Beclin-1 negative （P=0.041）. Overall survival rate of Beclin-1 positive renal carcinoma patients was significantly higher than Beclin-1 negative patients （P=0.008）. In addition, multivariate analysis showed that Beclin-1, tumor grade,tumor stage and lymph node status were independent prognostic factors of recurrence and death for renal cell carcinoma. Conclusion Beclin-1 low expression is an independent risk factor for poor prognosis of renal cancer. We can conclude that Beclin-1 may become a potential therapy target of renal carcinoma for individualized treatment.